Adoptive immunotherapy for Epstein-Barr virus-related lymphoma.
Epstein-Barr virus (EBV) causes opportunistic B cell lymphomas in patients whose cellular immunity is compromised. We have been investigating whether infusions of donor-derived, EBV-specific cytotoxic T cells can prevent and/or treat EBV-related lymphoproliferative disease in children receiving T cell-depleted bone marrow from HLA-matched, unrelated or HLA-mismatched, related donors. In this review, we discuss the rationale for this therapeutic approach, describe our experiences with the regimen thus far, and consider some future directions in immunotherapy.
Smith
C A
CA
Department of Hematology and Oncology, St. Jude Childrens' Research Hospital, Memphis, TN. 38105, USA.
Ng
C Y
CY
Loftin
S K
SK
Li
C
C
Heslop
H E
HE
Brenner
M K
MK
Rooney
C M
CM
D002648:Child; D006566:Herpesviridae Infections / Q000276:immunology* / Q000628:therapy*; D004854:Herpesvirus 4, Human; D006801:Humans; D007111:Immunity, Cellular; D016867:Immunocompromised Host; D016219:Immunotherapy, Adoptive; D016393:Lymphoma, B-Cell / Q000276:immunology / Q000628:therapy* / Q000821:virology*; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology; D014412:Tumor Virus Infections / Q000276:immunology* / Q000628:therapy*